CNTA

Centessa Pharmaceuticals plc

Fundamental data last updated:November 17, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

GB

Next Earnings Date

Not Scheduled

Business Summary

Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.

 


VALUATION

P/E

-22.75

Market Cap ($M USD)

$6.27B

Forward P/E

15.72

PEG

-1.23

PRICE TO SALES

0.00

PRICE TO BOOK

12.76

EV / EBITDA

-23.84

5-Year Average P/E

Free Cash Flow Yield

-3.34%

DCF Value

$1.12

Graham Number

N/A

Price to FCF

-29.96

EV to FCF

-29.70

Earnings Yield

-4.03%

FCF Yield

-3.34%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.63

Next Year EPS Growth Estimate

-$1.64

Next Year Revenue Growth Estimate

$3.09M

Return on Equity (ROE)

-60.37%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.02

Piotroski F-Score

2

Altman Z-Score

20.83

Return on Invested Capital (ROIC)

-42.41%

Current Ratio

9.53

Quick Ratio

9.53

Net Debt to EBITDA

0.21

Interest Coverage

-22.70

Gross Profit margin

0.00%

FCF PER SHARE

$-1.36

REVENUE PER SHARE

$0.00

Gainseekers Quantitative Analysis

Summary

Centessa Pharmaceuticals plc presents a perplexing valuation scenario. Despite a staggering market cap, the stock’s price has traded significantly above its DCF value, suggesting potential overvaluation. The Forward P/E of 15.72 indicates some optimism for future earnings, yet the negative Earnings Yield and ROIC highlight ongoing profitability challenges. The Altman Z-score of 20.83 suggests financial stability, but the negative earnings and cash flow metrics raise red flags about sustainable growth. Overall, the market may be mispricing the stock relative to its intrinsic value, with significant risks overshadowing potential rewards.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, Centessa is inherently positioned to leverage AI advancements in drug discovery and development. The industry's reliance on cutting-edge technology for research and innovation aligns well with AI integration. However, the company's current financial metrics suggest it may need to bolster its tech investments to fully capitalize on these opportunities.

The Bull Case

For the optimistic investor, Centessa's low Debt/Equity ratio of 0.015 and robust Current Ratio of 9.53 signal a strong liquidity position, providing a cushion for future growth initiatives. Despite a low Piotroski F-Score of 2, the company's financial stability is underscored by its impressive Altman Z-score. While the FCF Yield is negative, the potential for explosive sales growth next year could transform cash flow dynamics. This combination of liquidity and growth potential might attract those seeking undervalued opportunities with a long-term horizon.

The Bear Case

Yet, the bear case is hard to ignore. The stock's Price/Book ratio of 12.76 and Price/FCF of -29.96 suggest a valuation stretched to the limits, especially given its proximity to the 52-week high. The negative EPS and ROIC reflect a company struggling to convert its operations into profit, raising concerns about management's execution capabilities. With zero gross profit margin and a negative earnings surprise, the financial picture is bleak, casting doubt on the company's ability to deliver shareholder value in the near term.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$30.42

Institutional Ownership %

1-Year Beta

1.12

Insider Buying % (6 Mo)

Distance to 52-Week High

0.15%

Distance to 52-Week Low

68.44%

EARNINGS SURPRISE %

-36.84%

50-DAY SMA

$39.71

200-DAY SMA

$29.33

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.